Pancreatic cancer targeted therapy breakthrough: daraxonrasib
Key Questions
What survival benefit did daraxonrasib show in pancreatic cancer?
Daraxonrasib nearly doubled median survival from 6.6 to 13.2 months in Phase 3 trials for advanced pancreatic cancer. The KRAS G12D inhibitor targets over 90% of cases previously considered undruggable.
What is the regulatory and access status of daraxonrasib?
The therapy received an earlier FDA safe-to-proceed letter and has an active early access program with high demand. It is viewed as potentially practice-changing for a cancer with high unmet need.
How are experts and patients responding to the daraxonrasib results?
Oncologists describe the results as overcoming a long-standing treatment barrier, with PBS coverage including expert commentary and patient stories. The data follow positive Phase 1/2 findings and reinforce targeted therapy momentum.
Daraxonrasib (KRAS G12D inhibitor) nearly doubles median survival (13.2 vs 6.6 months) in Phase 3 for pancreatic cancer, targeting >90% of cases. Practice-changing for a deadly cancer with high unmet need; early access program already high demand. Follows earlier FDA safe-to-proceed letter and Phase 1/2 results. PBS article adds expert commentary and patient story (Ben Sasse).